Home
Up
Contacts
Blood Disorders
Chemotherapy
Transplantation
Blood Products
Bone Marrow
Links
PVT

8.5                                CRYOPRECIPITATE

 

 

Cryoprecipitate is prepared from fresh plasma and is rich in Factors VIII, XIII, Von Willebrand Factor and fibrinogen.

 

One unit of cryoprecipitate is derived from one unit of blood.

Volume varies between 10-40mL.

 

Use of cryoprecipitate is likely to be appropriate for:

 

Fibrinogen deficiency: May be appropriate where there is clinical bleeding, trauma, invasive procedure or DIC.

 

DIC: Fibrinogen deficiency is commonly encountered in DIC. At fibrinogen levels <1.0g/L and where there is clinical bleeding, use of cryoprecipitate to keep fibrinogen levels above 1.og/L may be indicated.  

 

Unless alternative therapies are unavailable, the use of cryoprecipitate is not considered appropriate in the treatment of:

 

·         Haemophilia

·         Von Willebrands’s disease

·         Deficiencies of Factor XIII or fibrinogen

 

 

Compatibilities

Recipient Group

Suitable Plasma Products

A

A, AB

B

B, AB

AB

AB, A

O

O, A, B, AB

 

·         Rh group doesn’t matter

·         Where group unknown use AB plasma

 

 

Where ABO group is unknown AB Cryo will be issued

 

 

Refer: Blood products summary & indications

          Summary of Transfusion Guidelines (NHMRC/ASBT 2002)

          Consent 1.0

 

 

 

OUTCOME

 

To ensure the safe and effective transfusion of Cryoprecipitate, in the appropriate amount at the appropriate time where the benefits of the transfusion out weigh the potential risks.

 

 

 

 

 

 

 

 

PERSONNEL ABLE TO PERFORM

Medical Officers

Registered Nurse + another RN or EN

 

 

 

EQUIPMENT

 

IV Therapy Chart (ordered for number of units, rate)

Blood component

Observations chart

Standard blood administration set

IV giving set

 

PRETRANSFUSION

 

Ensure integrity of vein with IV in situ before retrieving component from approved storage Collection of blood products 4.2

 

 

Ensure IV line (approved for blood administration) is primed with normal saline

 

Perform vital bedside identity check 6.1

 

Perform integrity check of component 6.2

 

 

Any discrepancy - STOP – contact the transfusion service provider immediately

 

ADMINISTRATION

 

Cryoprecipitate must be transfused with in 6 hours after thawing

 

·         Mix thoroughly by inversion before use

·         Transfuse via standard blood giving set

·         For first 15 minutes rate should be no more than 5mls/min unless otherwise indicated

·         Transfuse total dose over 30 mins, unless otherwise clinically indicated

·         Flush with saline at end of transfusion

 

OBSERVATIONS

·         Baseline TPR and BP at commencement of each unit

·         Repeat 15 minutes after commencement

·         Then on completion

 

The nurse must remain with the patient throughout the transfusion

·         Observe patient for change in vital signs

 

MODIFICATIONS

None